Presbyopia is the gradual loss of near focusing ability due to aging, which typically becomes noticeable in the early to mid-40s. This condition is treated by corrective eyeglasses, refractive surgery, lens implants, and FDA-approved eye drops like Vuity, Qlosi, and Vizz. The global presbyopia market is expected to grow to $13.30 billion in 2029 from the estimated $10.70 billion in 2025, according to a report by Business Research Co., a market intelligence firm.
The stock we are bringing to your attention today is Viatris Inc. (VTRS), which is developing a product for treating presbyopia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com